{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:36:31Z","timestamp":1793824591579,"version":"4.6.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00428-025-04306-z","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T09:55:48Z","timestamp":1760522148000},"page":"1087-1099","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The prognostic value of CLDN18.2 expression in pancreatic ductal adenocarcinoma: a systematic review and individual patient data meta-analysis"],"prefix":"10.1007","volume":"488","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0623-8135","authenticated-orcid":false,"given":"Francisco Cezar Aquino","family":"de Moraes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8707-4823","authenticated-orcid":false,"given":"Gustavo Tadeu Freitas Uch\u00f4a","family":"Matheus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Pimentel","family":"de Assump\u00e7\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4872-234X","authenticated-orcid":false,"given":"Rommel Mario Rodr\u00edguez","family":"Burbano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"4306_CR1","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1053\/j.gastro.2023.02.012","volume":"164","author":"EM Stoffel","year":"2023","unstructured":"Stoffel EM, Brand RE, Goggins M (2023) Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention. Gastroenterology 164:752\u2013765. https:\/\/doi.org\/10.1053\/j.gastro.2023.02.012","journal-title":"Gastroenterology"},{"key":"4306_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA Cancer J Clin 71:7\u201333. https:\/\/doi.org\/10.3322\/caac.21654","journal-title":"CA Cancer J Clin"},{"key":"4306_CR3","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM (2021) Pancreatic cancer: a review. JAMA 326:851\u2013862. https:\/\/doi.org\/10.1001\/jama.2021.13027","journal-title":"JAMA"},{"key":"4306_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1136227","author":"C Wang","year":"2023","unstructured":"Wang C, Wu N, Pei B et al (2023) Claudin and pancreatic cancer. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2023.1136227","journal-title":"Front Oncol"},{"key":"4306_CR5","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin U, Koslowski M, Dhaene K et al (2008) Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res 14:7624\u20137634. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1547","journal-title":"Clin Cancer Res"},{"key":"4306_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5387\/fms.2021-32","volume":"68","author":"M Sugimoto","year":"2022","unstructured":"Sugimoto M, Takagi T, Suzuki R et al (2022) Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer. Fukushima J Med Sci 68:1\u201310. https:\/\/doi.org\/10.5387\/fms.2021-32","journal-title":"Fukushima J Med Sci"},{"key":"4306_CR7","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s43018-022-00349-2","volume":"3","author":"AN Hosein","year":"2022","unstructured":"Hosein AN, Dougan SK, Aguirre AJ, Maitra A (2022) Translational advances in pancreatic ductal adenocarcinoma therapy. Nat Cancer 3:272\u2013286. https:\/\/doi.org\/10.1038\/s43018-022-00349-2","journal-title":"Nat Cancer"},{"key":"4306_CR8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.hoc.2015.04.006","volume":"29","author":"MA Lowery","year":"2015","unstructured":"Lowery MA, O\u2019Reilly EM (2015) Novel therapeutics for pancreatic adenocarcinoma. Hematol Oncol Clin North Am 29:777\u2013787. https:\/\/doi.org\/10.1016\/j.hoc.2015.04.006","journal-title":"Hematol Oncol Clin North Am"},{"key":"4306_CR9","first-page":"683","volume":"11","author":"M Katoh","year":"2003","unstructured":"Katoh M, Katoh M (2003) CLDN23 gene, frequently down-regulated in intestinal-type gastric cancer, is a novel member of CLAUDIN gene family. Int J Mol Med 11:683\u2013689","journal-title":"Int J Mol Med"},{"key":"4306_CR10","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.bbamem.2007.10.018","volume":"1778","author":"G Krause","year":"2008","unstructured":"Krause G, Winkler L, Mueller SL et al (2008) Structure and function of claudins. Biochim Biophys Acta 1778:631\u2013645. https:\/\/doi.org\/10.1016\/j.bbamem.2007.10.018","journal-title":"Biochim Biophys Acta"},{"key":"4306_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2009-10-8-235","volume":"10","author":"M Lal-Nag","year":"2009","unstructured":"Lal-Nag M, Morin PJ (2009) The claudins. Genome Biol 10:235. https:\/\/doi.org\/10.1186\/gb-2009-10-8-235","journal-title":"Genome Biol"},{"key":"4306_CR12","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1083\/jcb.141.7.1539","volume":"141","author":"M Furuse","year":"1998","unstructured":"Furuse M, Fujita K, Hiiragi T et al (1998) Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol 141:1539\u20131550. https:\/\/doi.org\/10.1083\/jcb.141.7.1539","journal-title":"J Cell Biol"},{"key":"4306_CR13","unstructured":"Claudin 4 protein expression in primary and metastatic pancreatic cancer: support for use as a therapeutic target - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/14983936\/. Accessed 3 Feb 2025"},{"key":"4306_CR14","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.21037\/tcr-19-1876","volume":"9","author":"JY Hong","year":"2020","unstructured":"Hong JY, An JY, Lee J et al (2020) Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer. Transl Cancer Res 9:3367\u20133374. https:\/\/doi.org\/10.21037\/tcr-19-1876","journal-title":"Transl Cancer Res"},{"key":"4306_CR15","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3390\/cancers14020290","volume":"14","author":"I Hashimoto","year":"2022","unstructured":"Hashimoto I, Oshima T (2022) Claudins and gastric cancer: an overview. Cancers (Basel) 14:290. https:\/\/doi.org\/10.3390\/cancers14020290","journal-title":"Cancers (Basel)"},{"key":"4306_CR16","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.addr.2005.01.006","volume":"57","author":"K Swisshelm","year":"2005","unstructured":"Swisshelm K, Macek R, Kubbies M (2005) Role of claudins in tumorigenesis. Adv Drug Deliv Rev 57:919\u2013928. https:\/\/doi.org\/10.1016\/j.addr.2005.01.006","journal-title":"Adv Drug Deliv Rev"},{"key":"4306_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100762","volume":"8","author":"Y Kubota","year":"2023","unstructured":"Kubota Y, Kawazoe A, Mishima S et al (2023) Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. ESMO Open 8:100762. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100762","journal-title":"ESMO Open"},{"key":"4306_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1132319","volume":"13","author":"J Chen","year":"2023","unstructured":"Chen J, Xu Z, Hu C et al (2023) Targeting CLDN18.2 in cancers of the gastrointestinal tract: new drugs and new indications. Front Oncol 13:1132319. https:\/\/doi.org\/10.3389\/fonc.2023.1132319","journal-title":"Front Oncol"},{"key":"4306_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-11980-w","volume":"24","author":"FCA de Moraes","year":"2024","unstructured":"de Moraes FCA, Pasqualotto E, Chavez MP et al (2024) Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials. BMC Cancer 24:240. https:\/\/doi.org\/10.1186\/s12885-024-11980-w","journal-title":"BMC Cancer"},{"key":"4306_CR20","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231217967","author":"Y Kubota","year":"2024","unstructured":"Kubota Y, Shitara K (2024) Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer. Ther Adv Med Oncol. https:\/\/doi.org\/10.1177\/17588359231217967","journal-title":"Ther Adv Med Oncol"},{"key":"4306_CR21","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1080\/17460441.2024.2370332","volume":"19","author":"Y Zeng","year":"2024","unstructured":"Zeng Y, Lockhart AC, Jin RU (2024) The preclinical discovery and development of zolbetuximab for the treatment of gastric cancer. Expert Opin Drug Discov 19:873\u2013886. https:\/\/doi.org\/10.1080\/17460441.2024.2370332","journal-title":"Expert Opin Drug Discov"},{"key":"4306_CR22","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1080\/1354750X.2024.2422965","volume":"29","author":"FCA de Moraes","year":"2024","unstructured":"de Moraes FCA, Rodrigues Sobreira LE, Cavalcanti Souza ME, Burbano RMR (2024) The role of CLDN18.2 in gastric cancer prognosis: a systematic review and meta-analysis. Biomarkers 29:528\u2013538. https:\/\/doi.org\/10.1080\/1354750X.2024.2422965","journal-title":"Biomarkers"},{"key":"4306_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4:1. https:\/\/doi.org\/10.1186\/2046-4053-4-1","journal-title":"Syst Rev"},{"key":"4306_CR24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1590\/S1677-5538.IBJU.2017.03.02","volume":"43","author":"WM Bernardo","year":"2017","unstructured":"Bernardo WM (2017) PRISMA statement and PROSPERO. Int Braz J Urol 43:383\u2013384. https:\/\/doi.org\/10.1590\/S1677-5538.IBJU.2017.03.02","journal-title":"Int Braz J Urol"},{"key":"4306_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2288-14-45","volume":"14","author":"CK-L Lo","year":"2014","unstructured":"Lo CK-L, Mertz D, Loeb M (2014) Newcastle-ottawa scale: comparing reviewers\u2019 to authors\u2019 assessments. BMC Med Res Methodol 14:45. https:\/\/doi.org\/10.1186\/1471-2288-14-45","journal-title":"BMC Med Res Methodol"},{"key":"4306_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"key":"4306_CR27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","volume":"21","author":"N Liu","year":"2021","unstructured":"Liu N, Zhou Y, Lee JJ (2021) IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol 21:111. https:\/\/doi.org\/10.1186\/s12874-021-01308-8","journal-title":"BMC Med Res Methodol"},{"key":"4306_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-25","volume":"14","author":"J IntHout","year":"2014","unstructured":"IntHout J, Ioannidis JP, Borm GF (2014) The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol 14:25. https:\/\/doi.org\/10.1186\/1471-2288-14-25","journal-title":"BMC Med Res Methodol"},{"key":"4306_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177\u2013188. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2","journal-title":"Control Clin Trials"},{"key":"4306_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12165394","author":"S Park","year":"2023","unstructured":"Park S, Shin K, Kim I-H et al (2023) Clinicopathological features and prognosis of resected pancreatic ductal adenocarcinoma patients with claudin-18 overexpression. J Clin Med. https:\/\/doi.org\/10.3390\/jcm12165394","journal-title":"J Clin Med"},{"key":"4306_CR31","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3892\/ol.2025.14886","volume":"29","author":"AM Valentini","year":"2025","unstructured":"Valentini AM, Arborea G, Grassi I et al (2025) Claudin 18.2: an attractive marker in pancreatic ductal adenocarcinoma. Oncol Lett 29:140. https:\/\/doi.org\/10.3892\/ol.2025.14886","journal-title":"Oncol Lett"},{"key":"4306_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102044","volume":"47","author":"SI Lyu","year":"2024","unstructured":"Lyu SI, Fretter C, Simon AG et al (2024) Extent and clinical significance of the therapy-relevant tight junction protein Claudin 18.2 in pancreatic ductal adenocarcinoma - real-world evidence. Transl Oncol 47:102044. https:\/\/doi.org\/10.1016\/j.tranon.2024.102044","journal-title":"Transl Oncol"},{"key":"4306_CR33","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.4251\/wjgo.v14.i7.1252","volume":"14","author":"X Wang","year":"2022","unstructured":"Wang X, Zhang C-S, Dong X-Y et al (2022) Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma. World J Gastrointest Oncol 14:1252\u20131264. https:\/\/doi.org\/10.4251\/wjgo.v14.i7.1252","journal-title":"World J Gastrointest Oncol"},{"key":"4306_CR34","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.14670\/HH-18-477","volume":"37","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Liu X, Zhou L et al (2022) Investigation of clinical application of claudin 18 isoform 2 in pancreatic ductal adenocarcinoma: a retrospective analysis of 302 chinese patients. Histol histopathol 37:1031\u20131040. https:\/\/doi.org\/10.14670\/HH-18-477","journal-title":"Histol histopathol"},{"key":"4306_CR35","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032882","volume":"102","author":"E Kayikcioglu","year":"2023","unstructured":"Kayikcioglu E, Y\u00fcceer RO (2023) The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes. Medicine (Baltimore) 102:e32882. https:\/\/doi.org\/10.1097\/MD.0000000000032882","journal-title":"Medicine (Baltimore)"},{"key":"4306_CR36","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1167\/iovs.09-3917","volume":"51","author":"HL Deissler","year":"2010","unstructured":"Deissler HL, Deissler H, Lang GE (2010) Inhibition of protein kinase C is not sufficient to prevent or reverse effects of VEGF165 on claudin-1 and permeability in microvascular retinal endothelial cells. Invest Ophthalmol Vis Sci 51:535\u2013542. https:\/\/doi.org\/10.1167\/iovs.09-3917","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4306_CR37","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2147\/CMAR.S38294","volume":"5","author":"L Ding","year":"2013","unstructured":"Ding L, Lu Z, Lu Q, Chen Y-H (2013) The claudin family of proteins in human malignancy: a clinical perspective. Cancer Manag Res 5:367\u2013375. https:\/\/doi.org\/10.2147\/CMAR.S38294","journal-title":"Cancer Manag Res"},{"key":"4306_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.643872","volume":"11","author":"BS Ungureanu","year":"2021","unstructured":"Ungureanu BS, Lungulescu C-V, Pirici D et al (2021) Clinicopathologic relevance of Claudin 18.2 expression in gastric cancer: a meta-analysis. Front Oncol 11:643872. https:\/\/doi.org\/10.3389\/fonc.2021.643872","journal-title":"Front Oncol"},{"key":"4306_CR39","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s12029-024-01141-4","volume":"56","author":"FCA de Moraes","year":"2025","unstructured":"de Moraes FCA, Sano VKT, Silva BL et al (2025) PD-1\/PD-L1 inhibitors increase pathological complete response in locally advanced gastric cancer: a meta-analysis and trial sequential analysis. J Gastrointest Cancer 56:49. https:\/\/doi.org\/10.1007\/s12029-024-01141-4","journal-title":"J Gastrointest Cancer"},{"key":"4306_CR40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejca.2018.05.007","volume":"100","author":"U Sahin","year":"2018","unstructured":"Sahin U, Schuler M, Richly H et al (2018) A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer. Eur J Cancer 100:17\u201326. https:\/\/doi.org\/10.1016\/j.ejca.2018.05.007","journal-title":"Eur J Cancer"},{"key":"4306_CR41","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1523096","volume":"8","author":"\u04e6 T\u00fcreci","year":"2019","unstructured":"T\u00fcreci \u04e6, Mitnacht-Kraus R, W\u00f6ll S et al (2019) Characterization of zolbetuximab in pancreatic cancer models. Oncoimmunology 8:e1523096. https:\/\/doi.org\/10.1080\/2162402X.2018.1523096","journal-title":"Oncoimmunology"},{"key":"4306_CR42","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","volume":"32","author":"U Sahin","year":"2021","unstructured":"Sahin U, T\u00fcreci \u00d6, Manikhas G et al (2021) FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol 32:609\u2013619. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.005","journal-title":"Ann Oncol"},{"key":"4306_CR43","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/PAS.0b013e31815701f3","volume":"32","author":"ZE Karanjawala","year":"2008","unstructured":"Karanjawala ZE, Illei PB, Ashfaq R et al (2008) New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8. Am J Surg Pathol 32:188\u2013196. https:\/\/doi.org\/10.1097\/PAS.0b013e31815701f3","journal-title":"Am J Surg Pathol"},{"key":"4306_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1271370","volume":"13","author":"X Xiang","year":"2023","unstructured":"Xiang X, Chen X, He Y et al (2023) Pancreatic cancer challenge in 52 Asian countries: age-centric insights and the role of modifiable risk factors (1990\u20132019). Front Oncol 13:1271370. https:\/\/doi.org\/10.3389\/fonc.2023.1271370","journal-title":"Front Oncol"},{"key":"4306_CR45","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1007\/s12094-024-03843-4","volume":"27","author":"FCA de Moraes","year":"2025","unstructured":"de Moraes FCA, de Oliveira Rodrigues ALS, Pasqualotto E et al (2025) Ethnic disparities in survival and progression among EGFR-mutated adenocarcinoma of lung cancer patients treated with tyrosine kinase inhibitors: a systematic review and meta-analysis. Clin Transl Oncol 27:3001\u20133014. https:\/\/doi.org\/10.1007\/s12094-024-03843-4","journal-title":"Clin Transl Oncol"},{"key":"4306_CR46","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10147-023-02317-x","volume":"28","author":"T Okusaka","year":"2023","unstructured":"Okusaka T, Nakamura M, Yoshida M et al (2023) Clinical practice guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Int J Clin Oncol 28:493\u2013511. https:\/\/doi.org\/10.1007\/s10147-023-02317-x","journal-title":"Int J Clin Oncol"},{"key":"4306_CR47","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.pan.2022.04.011","volume":"22","author":"J Chen","year":"2022","unstructured":"Chen J, Chen H, Zhang T et al (2022) Burden of pancreatic cancer along with attributable risk factors in China from 1990 to 2019, and projections until 2030. Pancreatology 22:608\u2013618. https:\/\/doi.org\/10.1016\/j.pan.2022.04.011","journal-title":"Pancreatology"},{"key":"4306_CR48","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.immuni.2024.04.021","volume":"57","author":"F De Sanctis","year":"2024","unstructured":"De Sanctis F, Dusi S, Caligola S et al (2024) Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immunity in pancreatic cancer. Immunity 57:1378-1393.e14. https:\/\/doi.org\/10.1016\/j.immuni.2024.04.021","journal-title":"Immunity"},{"key":"4306_CR49","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-025-04222-2","author":"C Luchini","year":"2025","unstructured":"Luchini C, Matkowskyj KA, Kuwata T et al (2025) Claudin-18.2 immunohistochemical evaluation in pancreatic cancer specimens: review and recommendations for routine testing and scoring. Virchows Arch. https:\/\/doi.org\/10.1007\/s00428-025-04222-2","journal-title":"Virchows Arch"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04306-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-025-04306-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04306-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:59:05Z","timestamp":1778738345000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-025-04306-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4306"],"URL":"https:\/\/doi.org\/10.1007\/s00428-025-04306-z","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Disclosure"}},{"value":"No ethical approval was required for this systematic review with meta-analysis, as all data were already published in peer-reviewed jour\u00adnals. Furthermore, no patients or animals were involved in the design, conduct, or interpretation of our study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"\u00a0Institutional review board"}},{"value":"During the preparation of this manuscript, the authors utilized ChatGPT, GPT-4o model developed by OpenAI., to enhance the readability and language of the text. Following the use of this tool, the authors thoroughly reviewed and edited the content as necessary and assume full responsibility for the final version of the publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies in the writing process"}},{"value":"The authors declare that they have no competing interests.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}